Multidrug resistance in acute leukemia: A conserved physiologic function

Alan F. List, Catherine S Perry

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Native resistance to conventional chemotherapy remains an important cause of treatment failure in the adult acute leukemias. Delineation of cellular mechanisms of drug resistance therefore represents a prerequisite to the development of more effective treatment strategies. The multidrug resistance (MDR) phenotype represents one such mechanism of resistance with direct clinical relevance. This phenotype occurs normally in certain mammalian tissues, and is detectable in tumor cell lines selected for resistance to naturally occurring antineoplastics. The mdr1 gene or its glycoprotein product, P-glycoprotein, is detected with high frequency in secondary acute myeloid leukemia (AML) and poor-risk subsets of acute lymphoblastic leukemia. In prospective studies in AML, MDR overexpression is an independent determinant of response to treatment and overall survival with conventional-dose induction regimens. Investigations of mdr1 regulation in normal hematopoietic elements has shown a pattern which corresponds to its regulation in acute leukemia, explaining the linkage of mdr1 to specific cellular phenotypes. Therapeutic trials are now in progress to test the ability of various MDR-reversal agents to restore chemotherapy sensitivity in high-risk acute leukemias.

Original languageEnglish (US)
Pages (from-to)9-14
Number of pages6
JournalLeukemia and Lymphoma
Volume8
Issue number1-2
DOIs
StatePublished - 1992

Fingerprint

Multiple Drug Resistance
Leukemia
Phenotype
Acute Myeloid Leukemia
Drug Therapy
P-Glycoprotein
Tumor Cell Line
Treatment Failure
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Resistance
Antineoplastic Agents
Glycoproteins
Therapeutics
Prospective Studies
Genes

Keywords

  • Acute leukemia
  • MDR
  • Multidrug resistance

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Multidrug resistance in acute leukemia : A conserved physiologic function. / List, Alan F.; Perry, Catherine S.

In: Leukemia and Lymphoma, Vol. 8, No. 1-2, 1992, p. 9-14.

Research output: Contribution to journalArticle

@article{6bd7959b831f4e1c9b1ffd39d4b70375,
title = "Multidrug resistance in acute leukemia: A conserved physiologic function",
abstract = "Native resistance to conventional chemotherapy remains an important cause of treatment failure in the adult acute leukemias. Delineation of cellular mechanisms of drug resistance therefore represents a prerequisite to the development of more effective treatment strategies. The multidrug resistance (MDR) phenotype represents one such mechanism of resistance with direct clinical relevance. This phenotype occurs normally in certain mammalian tissues, and is detectable in tumor cell lines selected for resistance to naturally occurring antineoplastics. The mdr1 gene or its glycoprotein product, P-glycoprotein, is detected with high frequency in secondary acute myeloid leukemia (AML) and poor-risk subsets of acute lymphoblastic leukemia. In prospective studies in AML, MDR overexpression is an independent determinant of response to treatment and overall survival with conventional-dose induction regimens. Investigations of mdr1 regulation in normal hematopoietic elements has shown a pattern which corresponds to its regulation in acute leukemia, explaining the linkage of mdr1 to specific cellular phenotypes. Therapeutic trials are now in progress to test the ability of various MDR-reversal agents to restore chemotherapy sensitivity in high-risk acute leukemias.",
keywords = "Acute leukemia, MDR, Multidrug resistance",
author = "List, {Alan F.} and Perry, {Catherine S}",
year = "1992",
doi = "10.3109/10428199209049812",
language = "English (US)",
volume = "8",
pages = "9--14",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Multidrug resistance in acute leukemia

T2 - A conserved physiologic function

AU - List, Alan F.

AU - Perry, Catherine S

PY - 1992

Y1 - 1992

N2 - Native resistance to conventional chemotherapy remains an important cause of treatment failure in the adult acute leukemias. Delineation of cellular mechanisms of drug resistance therefore represents a prerequisite to the development of more effective treatment strategies. The multidrug resistance (MDR) phenotype represents one such mechanism of resistance with direct clinical relevance. This phenotype occurs normally in certain mammalian tissues, and is detectable in tumor cell lines selected for resistance to naturally occurring antineoplastics. The mdr1 gene or its glycoprotein product, P-glycoprotein, is detected with high frequency in secondary acute myeloid leukemia (AML) and poor-risk subsets of acute lymphoblastic leukemia. In prospective studies in AML, MDR overexpression is an independent determinant of response to treatment and overall survival with conventional-dose induction regimens. Investigations of mdr1 regulation in normal hematopoietic elements has shown a pattern which corresponds to its regulation in acute leukemia, explaining the linkage of mdr1 to specific cellular phenotypes. Therapeutic trials are now in progress to test the ability of various MDR-reversal agents to restore chemotherapy sensitivity in high-risk acute leukemias.

AB - Native resistance to conventional chemotherapy remains an important cause of treatment failure in the adult acute leukemias. Delineation of cellular mechanisms of drug resistance therefore represents a prerequisite to the development of more effective treatment strategies. The multidrug resistance (MDR) phenotype represents one such mechanism of resistance with direct clinical relevance. This phenotype occurs normally in certain mammalian tissues, and is detectable in tumor cell lines selected for resistance to naturally occurring antineoplastics. The mdr1 gene or its glycoprotein product, P-glycoprotein, is detected with high frequency in secondary acute myeloid leukemia (AML) and poor-risk subsets of acute lymphoblastic leukemia. In prospective studies in AML, MDR overexpression is an independent determinant of response to treatment and overall survival with conventional-dose induction regimens. Investigations of mdr1 regulation in normal hematopoietic elements has shown a pattern which corresponds to its regulation in acute leukemia, explaining the linkage of mdr1 to specific cellular phenotypes. Therapeutic trials are now in progress to test the ability of various MDR-reversal agents to restore chemotherapy sensitivity in high-risk acute leukemias.

KW - Acute leukemia

KW - MDR

KW - Multidrug resistance

UR - http://www.scopus.com/inward/record.url?scp=0026673587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026673587&partnerID=8YFLogxK

U2 - 10.3109/10428199209049812

DO - 10.3109/10428199209049812

M3 - Article

C2 - 1283551

AN - SCOPUS:0026673587

VL - 8

SP - 9

EP - 14

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -